Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Stephen BagleyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. [email protected]Zev A. BinderCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USALamia LamraniClinical Immunology Laboratory, Institut Curie, Paris, FranceEliana MarinariAgora Cancer Research Center, Lausanne, SwitzerlandArati DesaiDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMacLean P. NasrallahDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAEileen MaloneyDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USASteven BremDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USARobert A. LustigDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAGoldie KurtzDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMichelle Alonso‐BasantaDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAPierre‐Emmanuel BontéINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, FranceChristel GoudotINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, FranceWilfrid RicherDepartment of Translational Research, PSL Research University, Institut Curie Research Center, Paris, FranceEliane PiaggioINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, FranceShawn KothariDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USALéa GuyonnetCytometry Platform, CurieCoreTech, Institut Curie, Paris, FranceCoralie L. GuérinCytometry Platform, CurieCoreTech, Institut Curie, Paris, FranceJoshua J. WaterfallDepartment of Translational Research, PSL Research University, Institut Curie Research Center, Paris, FranceSuyash MohanDepartment of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAWei‐Ting HwangDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAOliver Y. TangGBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMeghan LogunCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMeghna BhattacharyyaCooper Medical School of Rowan University, Camden, NJ, USAKelly MarkowitzDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USADevora DelmanDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAAmy MarshallCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAE. John WherryDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USASebastián AmigorenaINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, FranceGregory L. BeattyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAJennifer L. BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USAElizabeth O. HexnerDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USADenis MiglioriniAgora Cancer Research Center, Lausanne, SwitzerlandCécile AlanioClinical Immunology Laboratory, Institut Curie, Paris, France. [email protected]Donald M. O’RourkeCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
2024en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0